$3.02 -0.03 (-0.98%)
11/24/2009 4:00 PM

Vical, Inc. (VICL)

CAPS Rating: 2 out of 5

The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Results 1 - 15 of 15

Recs

0
Member Avatar carsondyle (30.99) Submitted: 11/9/2009 9:48:28 AM : Outperform Start Price: $3.03 VICL Score: -5.52

I like the pipeline. I think this is a long term buy, but in the short run stock may not make any dramatic moves. I also like SNGX if your looking for big gain potential next 6 to 12 months.

Recs

0
Member Avatar RootnToot (36.35) Submitted: 11/6/2009 12:18:28 PM : Outperform Start Price: $3.01 VICL Score: -3.30

Rolling the dice. After all, SOMEONE has to win the lottery, why not me?!!

Recs

0
Member Avatar crichton1 (35.28) Submitted: 10/8/2009 8:52:37 PM : Outperform Start Price: $3.86 VICL Score: -25.84

Good entry point for medical products approved next year.

Recs

0
Member Avatar AzUKHiker (< 20) Submitted: 10/1/2009 3:14:08 PM : Outperform Start Price: $4.03 VICL Score: -32.15

Stockscouter rating of 10 and high 3 and 12 month RS

Recs

0
Member Avatar NoDoughBro (70.80) Submitted: 8/31/2009 1:27:25 PM : Outperform Start Price: $3.00 VICL Score: -4.38

Because of the flu it's going to go woo...woo...wooo!

Recs

3
Member Avatar zzlangerhans (99.53) Submitted: 6/15/2009 12:48:50 PM : Underperform Start Price: $2.59 VICL Score: +4.34

I might have adopted a "wait and see" approach to Vical if it wasn't for the 100M picking threshold. I've been a green thumber on Vical before and had to watch it nearly go sub-1 before eventually squeaking out with a positive score. While Vical may be still be undervalued for the long term, the short term share price is too wrapped up in swine flu nonsense which I've been steadily betting against. Prior to swine flu, Vical was not very active in the pandemic influenza department and was focusing mainly on a CMV vaccine and the weird tumor vaccine Allovectin-7, neither of which was likely to rock the world anytime soon. Of course swine flu has made all of these companies influenza powerhouses long enough to get their stocks doubled and hopefully permit juicy dilutive financings. We shall see how all that works out for the shareholders.

Recs

0
Member Avatar KnowWhen2Holdem (< 20) Submitted: 7/6/2008 6:42:06 PM : Outperform Start Price: $3.52 VICL Score: -4.51

DNA plasmid technology for pandemic flu (results out in 8/08), peripheral artery disease partnered with ANGES (already approved in Japan) and SNY, Melanoma, CMV, etc. Other iron in fire is Vaxfectin as adjuvant for vaccines. Stock has gone from fantasy land pricing to reality. No current interest with slowly increasing volume and price. Very low capitalization (approximately 140 mm). This is one of those risky biotechs with big up and downside.

Recs

0
Member Avatar Macronomica (< 20) Submitted: 6/16/2008 7:16:50 AM : Outperform Start Price: $3.54 VICL Score: +1.78

Vical Pandemic Influenza Vaccines Provide Complete Protection in Animal Studies against H5N1

Vical announced today the publication of results demonstrating that pandemic influenza DNA vaccines formulated with the company's patented Vaxfectin(R) adjuvant provided complete protection of mice and ferrets against lethal challenge with a highly pathogenic strain of H5N1 influenza virus.

Recs

0
Member Avatar ipericles (75.94) Submitted: 3/13/2008 7:41:51 PM : Outperform Start Price: $3.34 VICL Score: +3.30

Company has innovative technologies that will make certain remedies (vaccines and the like) more effective in their intended use.

Recs

0
Member Avatar EtownDunk (24.80) Submitted: 10/27/2007 1:03:09 AM : Outperform Start Price: $5.19 VICL Score: -17.36

Nice Cash Flow Growth (TTM vs Prior), Good Oper Margin (TTM vs. 5yr) and relatively low Price/Book

Recs

0
Member Avatar tharlow (< 20) Submitted: 8/22/2007 3:28:35 AM : Outperform Start Price: $4.82 VICL Score: -17.36

Science will prevail.

Recs

0
Member Avatar Pluymen (< 20) Submitted: 1/29/2007 3:54:30 PM : Outperform Start Price: $6.32 VICL Score: -35.17

Anticipate a buyout by big pharma. If not, stock price will rise with positive news flow of trial results.

Recs

0
Member Avatar moorefish (< 20) Submitted: 11/19/2006 7:02:32 AM : Outperform Start Price: $6.43 VICL Score: -37.14

Out of fashion, but possibly amazing jabs on the way

Recs

0
Member Avatar deugei1 (74.07) Submitted: 10/22/2006 1:01:56 AM : Outperform Start Price: $5.93 VICL Score: -35.34

Great test results, and it's flu season.

Recs

0
Member Avatar guy1818181818 (< 20) Submitted: 9/27/2006 5:57:27 PM : Outperform Start Price: $4.96 VICL Score: -27.23

big risk but has huge potential

Results 1 - 15 of 15

Featured Broker Partners